{"filing":{"accession_number":"0001193125-26-378838","cik":"0001699382","ticker":"PMVP","company_name":"PMV Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-31","primary_document":"d113784d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526378838/d113784d8k.htm"},"events":[{"id":31106,"run_id":28529,"accession_number":"0001193125-26-378838","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"PMV Pharmaceuticals entered into an underwriting agreement on August 31, 2026 and priced a public offering of approximately $50.8 million in gross proceeds, consisting of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 common stock warrants. The company intends to use proceeds to fund late-stage clinical development and commercialization of rezatapopt.","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33905,"accession_number":"0001193125-26-378838","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PMV Pharmaceuticals entered into an underwriting agreement on August 31, 2026 for a public offering of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 common stock warrants, with expected gross proceeds of approximately $50.8 million. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 (Entry into a Material Definitive Agreement) via the underwriting agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:05:40.215615+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33906,"accession_number":"0001193125-26-378838","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PMV Pharma announced the pricing of an underwritten public offering of approximately $50.8 million in gross proceeds, consisting of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 accompanying warrants. This is a material dilutive equity issuance that raises capital through the sale of common stock and warrant securities, typical of small-cap biotech companies funding clinical development. The company explicitly states it will use proceeds to fund late-stage clinical development and commercialization of rezatapopt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:05:40.215615+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33905,"accession_number":"0001193125-26-378838","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PMV Pharmaceuticals entered into an underwriting agreement on August 31, 2026 for a public offering of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 common stock warrants, with expected gross proceeds of approximately $50.8 million. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 (Entry into a Material Definitive Agreement) via the underwriting agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:05:40.215615+00:00","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-09-01"},{"id":33906,"accession_number":"0001193125-26-378838","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PMV Pharma announced the pricing of an underwritten public offering of approximately $50.8 million in gross proceeds, consisting of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 accompanying warrants. This is a material dilutive equity issuance that raises capital through the sale of common stock and warrant securities, typical of small-cap biotech companies funding clinical development. The company explicitly states it will use proceeds to fund late-stage clinical development and commercialization of rezatapopt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:05:40.215615+00:00","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-09-01"}]}